Pleiotropic and epistatic effects in sickle cell anemia

镰状细胞性贫血的多效性和上位性作用

基本信息

  • 批准号:
    6641203
  • 负责人:
  • 金额:
    $ 81.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-09-30 至 2006-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Sickle cell anemia (SCA) is the paradigmatic monogenic disease, but the sickle mutation is not sufficient to define the phenotype. Pleiotropic effects influence complications. Secondly, SCA exhibits an intense inter-individual variability, which is likely to be the effect of epistatic genes, since heritability of major determinants of severity exhibit high concordance in monozygote twins (89%). The aim of this project is to define the epistatic/pleiotropic genes involved in sickle-cell mediated vaso-occlusion in different organs, building on our years of working on the genetics and pathophysiology of this problem in mice and men. We will engage in the detection of genes involved in sickle cell-mediated vaso-occlusion in animal models, in the detection of genes involved in sickle cell-mediated vaso-occlusion in patients with sickle cell anemia and in the detection of genes involved in vaso-occlusive and vaso-proliferative processes in sickle cell retina and choroid and in cerebrovascular complications in sickle cell anemia, which our previous work has defined as a special case. The experimental design is the following: Approach 1: Appropriate tissues in sickle transgenic mice and other animal models -+ RNA -+ expression chips -> select the higher express genes and the lower expressing genes vs control -+ BLAST --> the selected human genes will be analyzed for potential epistatic effects by SNP arrays and by sequencing to define polymorphism in appropriately defined human sickle cell anemia DNA samples. Approach 2: In the complications without animal models, but candidate genes based on human pathophysiological data, SNPs and sequencing analyzes will be performed in sickle cell anemia patients with a particular complication vs sickle cell anemia patients without it. Of course, appropriate matching age groups will be selected to assure that the complication is no longer possible in the control group. Genes defined by these two approaches will be followed in animal models when available (KO or over expression, or generated for further confirmation. Members of this proposal have special expertise in retinal, cerebro-vascular problems and statistical analysis. Our institution has well established expertise in transgenic mice, microcirculatory preparations, hemopoiesis and patient follow-up, as a well as experienced SNP, sequencing and CHIP expression facilities.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ronald L Nagel其他文献

Compound Heterozygosity for Hemoglobin and Korle-Bu: Moderate Microcytic Hemolytic Anemia and Acceleration of Crystal Formation
  • DOI:
    10.1182/blood.v82.6.1907.1907
  • 发表时间:
    1993-09-15
  • 期刊:
  • 影响因子:
  • 作者:
    Ronald L Nagel;Margaret J. Lin;H. Ewa Witkowska;Mary E. Fabry;Marc Bestak;Rhoda Elison Hirsch
  • 通讯作者:
    Rhoda Elison Hirsch
Effects of Hydroxyurea (HU) on Maximum Urine Concentrating Ability and Hematological Indices in Children with Hb SC Disease
  • DOI:
    10.1203/00006450-199904020-00877
  • 发表时间:
    1999-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Rathi V Iyer;Radhakrishna Baliga;Ronald L Nagel;Carlo Brugnara;Kent Kirchner;Martin H Steinberg
  • 通讯作者:
    Martin H Steinberg

Ronald L Nagel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ronald L Nagel', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    7406851
  • 财政年份:
    2007
  • 资助金额:
    $ 81.56万
  • 项目类别:
SICKLE CELL
镰状细胞
  • 批准号:
    7608054
  • 财政年份:
    2007
  • 资助金额:
    $ 81.56万
  • 项目类别:
SICKLE CELL
镰状细胞
  • 批准号:
    7375458
  • 财政年份:
    2005
  • 资助金额:
    $ 81.56万
  • 项目类别:
SICKLE CELL ANEMIA
镰状细胞性贫血
  • 批准号:
    7203419
  • 财政年份:
    2004
  • 资助金额:
    $ 81.56万
  • 项目类别:
Bronx Comprehensive Sickle Cell Center
布朗克斯综合镰状细胞中心
  • 批准号:
    6534949
  • 财政年份:
    2003
  • 资助金额:
    $ 81.56万
  • 项目类别:
Bronx Comprehensive Sickle Cell Center
布朗克斯综合镰状细胞中心
  • 批准号:
    6887400
  • 财政年份:
    2003
  • 资助金额:
    $ 81.56万
  • 项目类别:
Bronx Comprehensive Sickle Cell Center
布朗克斯综合镰状细胞中心
  • 批准号:
    7076126
  • 财政年份:
    2003
  • 资助金额:
    $ 81.56万
  • 项目类别:
Bronx Comprehensive Sickle Cell Center
布朗克斯综合镰状细胞中心
  • 批准号:
    7261992
  • 财政年份:
    2003
  • 资助金额:
    $ 81.56万
  • 项目类别:
Bronx Comprehensive Sickle Cell Center
布朗克斯综合镰状细胞中心
  • 批准号:
    6769383
  • 财政年份:
    2003
  • 资助金额:
    $ 81.56万
  • 项目类别:
SICKLE CELL ANEMIA
镰状细胞性贫血
  • 批准号:
    7045740
  • 财政年份:
    2003
  • 资助金额:
    $ 81.56万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 81.56万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
  • 批准号:
    10762827
  • 财政年份:
    2023
  • 资助金额:
    $ 81.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了